Read the September edition of Pharmafocus online now!
pharmafile | September 12, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, brexit, lung cancer, medicinal cannabis, pharma
The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!
With a new Prime Minister, a renewed drive to vacate the European Union by the fixed date of 31 October by any means necessary, but a distinct lack of any tangible negotiation strategy – or indeed, any evidence of negotiations at all – the UK looks to be hurtling towards a no-deal Brexit. This appears to suggest that warnings from the life sciences industry over the dangers of such an exit on medicine access, research collaboration, talent retention and more have been ignored, or deemed a worthy trade-off. If all is as it appears, it’s a grim picture; still, the industry powers on.
In our cover story this month, you can read the full story of the shocking revelation that Novartis knowingly submitted faulty data in support of its FDA application for its gene therapy Zolgensma – the world’s most expensive treatment at $2.1 million. While the company has tried to explain and justify its actions, the news was unsurprisingly met with scorn reaching all the way up to Democratic Presidential candidates Elizabeth Warren and Bernie Sanders, while senators called for a “forceful response” from the FDA.
Medicinal cannabis continues to be a topic of intense debate with regards to driving research and improving patient outcomes, with legalisation becoming an ever more pressing question for Western governments to answer. In our September issue, we delve into the subject with a special three-piece focus exploring the substance’s potential for research and how attitudes towards it are shifting around the world.
Elsewhere in the issue, we also investigate the latest, greatest effort to supercharge lung cancer survival: the Lung Ambition Alliance. We speak to the core members of the alliance – the International Association for the Study of Lung Cancer, the Global Lung Cancer Coalition, Guardant Health and AstraZeneca – to discover why this collaboration will succeed in their ambitious goals where others have failed.
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
